Investigational new drug applications; clinical holds--FDA. Direct final rule.
The Food and Drug Administration (FDA) is amending its regulations governing investigational new drug applications (IND's) for human drug and biological products. This action amends the IND clinical hold requirements to state that the agency will respond in writing to a sponsor's request that a clinical hold be removed from an investigation within 30-calendar days of the agency's receipt of the request and the sponsor's complete response to the issue(s) that led to the clinical hold. FDA is taking this action in accordance with provisions of the Food and Drug Administration Modernization Act of 1997 (the Modernization Act). Elsewhere in this issue of the Federal Register, FDA is publishing a companion proposed rule under FDA's usual procedure for notice-and-comment rulemaking to provide a procedural framework to finalize the rule in the event the agency receives significant adverse comments and withdraws this direct final rule.
D017277:Drug Approval / Q000331:legislation & jurisprudence*; D015507:Drugs, Investigational; D017408:Guidelines as Topic; D011050:Policy Making; D014481:United States; D014486:United States Food and Drug Administration
D015507:Drugs, Investigational